Search

Displaying results 2461 - 2470 of 4691 in total
  1. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]

    Products: Ak Tate Oph Sus 1%
  2. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia

  3. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  4. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … [A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip

  5. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. … Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6).

  6. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.

  7. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction

  8. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    Many conditions are characterized by depleted bone marrow, including myelodysplastic syndrome (MDS), a form of pre-leukemia in which the bone marrow produces insufficient levels of one or more of the 3 … It acts intracellularly on the MAPK signaling pathway by activating ERK2.

  9. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

  10. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.